Reviva to Participate in the Citizens Life Sciences Conference
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a fireside chat format.
The presentation is scheduled for Thursday, May 8, 2025, at 10:30 a.m. ET. Reviva focuses on developing therapies for:
- Central nervous system (CNS) diseases
- Inflammatory conditions
- Cardiometabolic diseases
The company aims to address unmet medical needs in these therapeutic areas. A webcast link has been provided for interested parties to access the presentation.
Reviva Pharmaceuticals (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata di sviluppo, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York. Il Fondatore, Presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., presenterà un aggiornamento aziendale attraverso un formato di conversazione informale.
La presentazione è prevista per giovedì 8 maggio 2025 alle 10:30 ET. Reviva si concentra sullo sviluppo di terapie per:
- Malattie del sistema nervoso centrale (SNC)
- Condizioni infiammatorie
- Malattie cardiometaboliche
L'azienda mira a soddisfare bisogni medici non ancora coperti in questi ambiti terapeutici. È stato fornito un link per il webcast, per consentire agli interessati di seguire la presentazione.
Reviva Pharmaceuticals (NASDAQ: RVPH), una compañía farmacéutica en etapa avanzada, ha anunciado su participación en la próxima Citizens Life Sciences Conference en Nueva York. El fundador, presidente y CEO de la empresa, Laxminarayan Bhat, Ph.D., ofrecerá una actualización corporativa mediante un formato de charla informal.
La presentación está programada para el jueves 8 de mayo de 2025 a las 10:30 a.m. ET. Reviva se enfoca en desarrollar terapias para:
- Enfermedades del sistema nervioso central (SNC)
- Condiciones inflamatorias
- Enfermedades cardiometabólicas
La compañía busca cubrir necesidades médicas no satisfechas en estas áreas terapéuticas. Se ha proporcionado un enlace para la transmisión en línea para que los interesados puedan acceder a la presentación.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 후기 단계의 제약 회사로서 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여한다고 발표했습니다. 회사의 창립자이자 사장 겸 CEO인 Laxminarayan Bhat 박사가 대담 형식으로 회사 현황을 업데이트할 예정입니다.
발표는 2025년 5월 8일 목요일 오전 10시 30분(동부 시간)에 예정되어 있습니다. Reviva는 다음 분야의 치료제 개발에 집중하고 있습니다:
- 중추신경계(CNS) 질환
- 염증성 질환
- 심장대사 질환
회사는 이들 치료 분야에서 충족되지 않은 의료 수요를 해결하는 것을 목표로 하고 있습니다. 관심 있는 분들을 위해 웹캐스트 링크가 제공되었습니다.
Reviva Pharmaceuticals (NASDAQ : RVPH), une société pharmaceutique en phase avancée, a annoncé sa participation à la prochaine Citizens Life Sciences Conference à New York. Le fondateur, président et PDG de l'entreprise, Laxminarayan Bhat, Ph.D., présentera une mise à jour de la société sous forme de discussion informelle.
La présentation est prévue le jeudi 8 mai 2025 à 10h30, heure de l'Est. Reviva se concentre sur le développement de thérapies pour :
- Les maladies du système nerveux central (SNC)
- Les affections inflammatoires
- Les maladies cardiométaboliques
L'entreprise vise à répondre aux besoins médicaux non satisfaits dans ces domaines thérapeutiques. Un lien pour le webcast a été mis à disposition pour permettre aux intéressés d'accéder à la présentation.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein Pharmaunternehmen in der späten Entwicklungsphase, hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York angekündigt. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird ein Unternehmensupdate in Form eines informellen Gesprächs präsentieren.
Die Präsentation ist für Donnerstag, den 8. Mai 2025, um 10:30 Uhr ET geplant. Reviva konzentriert sich auf die Entwicklung von Therapien für:
- Zentralnervensystem-Erkrankungen (ZNS)
- Entzündliche Erkrankungen
- Kardiometabolische Erkrankungen
Das Unternehmen hat das Ziel, ungedeckte medizinische Bedürfnisse in diesen therapeutischen Bereichen zu adressieren. Ein Webcast-Link wurde bereitgestellt, damit Interessierte die Präsentation verfolgen können.
- Late-stage pharmaceutical company status indicates advanced product pipeline
- Diversified therapeutic focus across CNS, inflammatory and cardiometabolic diseases
- None.
CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY.
Citizens Life Sciences Conference
Format: Corporate Update / Fireside Chat
Date: Thursday, May 8, 2025
Time: 10:30 a.m. ET
Location: New York, NY
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva (RVPH) presenting at the Citizens Life Sciences Conference 2025?
What type of presentation will RVPH give at the Citizens Life Sciences Conference?
What therapeutic areas does Reviva (RVPH) focus on developing treatments for?
Is the Citizens Life Sciences Conference presentation by RVPH available online?
What stage pharmaceutical company is RVPH in 2025?
